Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
Posted on: Wednesday, 3 June 2009, 09:36 CDT
The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit. StemEx(R) is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA).
Excel is a study that gives clinicians the opportunity to explore a new path in the pursuit of a therapeutic treatment for patients with blood cancers. Cord blood can successfully be used to treat leukemia and lymphoma in young children. It stands to reason therefore that the same basic source could also be used to effectively treat adolescents and adults. The Excel trial provides an opportunity to determine if StemEx can indeed make this a possibility.
Cord blood has less matching requirements than bone marrow or peripheral blood transplants, providing the potential to increase the number of suitable transplant matches and to shorten the time it can take to find a match. However, there are a limited number of stem/progenitor cells in cord blood, enabling a quantity sufficient generally only for pediatric treatment. StemEx(R) employs a technology that expands this small number of cord blood stem/progenitor cells, increasing their therapeutic capacity for transplantation in adolescents and adults.
It is estimated that more than 11,000 patients in the European Union are in need of an allogeneic (from a source outside of the patient's body) hematopoietic (blood) stem cell transplantation. This is an unofficial figure calculated based on the method proposed by the US government's General Accounting Office (GAO) report and The EBMT Activity Survey 2006 on Hematopoietic Stem Cell Transplantation: Focus on the Use of Cord Blood Products.
"We are enthusiastic about working with these five outstanding hospitals
in
About Gamida Cell
Gamida Cell Ltd. is a world leader in stem cell expansion technologies
and therapeutic products. The company is developing a pipeline of products in
stem cell transplantation and in tissue regeneration to effectively treat
debilitating and often fatal illnesses such as cancer, hematological,
autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates
contain populations of adult stem cells, selected from non-controversial
sources such as umbilical cord blood and bone marrow, which are expanded in
culture. Gamida Cell was successful in translating these proprietary
expansion technologies into robust and validated manufacturing processes
under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a
therapy for patients with blood cancers in an international pivotal trial at
leading transplant centers in the U.S.,
Press contacts:
SOURCE Gamida Cell LTD
Source: PR Newswire
Related Articles
- StemCyte, Inc. Reaches 1,000th Cord Blood Stem Cell Shipment for Transplant Milestone
- Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells
- Stanford Scientists Pinpoint Key Proteins in Blood Stem Cell Replication
- Blood Stem Cells Originate in the Placenta
- StemCyte Presents Six Abstracts on the Applications of Plasma-Depleted Umbilical Cord Blood Stem Cell Products at BMT Tandem Meetings
- New Program Offers Expectant Parents and Physicians Option to Save Umbilical Cord Blood Stem Cells at Birth
- StemCyte(R), Inc. Surpasses 250th Cord Blood Stem Cell Transplant
- Researchers Identify Genes Involved with Blood Stem Cell Development
- Identifying Blood Stem Cells Is a SLAM Dunk
- A Phase I Trial Combining High-Dose ^Sup 90^Y-Labeled Humanized Anti- CEA Monoclonal Antibody With Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
 |
 |
User Comments (0)
RSS Feeds